Effects of different doses of clopidogrel on plasma hs-CRP and Lp-PLA2 in patients with acute coronary syndrome after PCI

Objective To investigate the effects of double-dose clopidogrel on plasma high-sensitivity C-reactive protein( hs-CRP) and lipoprotein-associated phospholipase A2( Lp-PLA2) in patients with acute coronary syndrome( ACS) after PCI. Methods A total of 162 patients with ACS after PCI were randomly divided into two groups: the observation group( n = 81) and the control group( n = 81). All patients before PCI were given aspirin 300 mg and clopidogrel 300 mg.After PCI,patients in the observation group were given oral administration of clopidogrel 150 mg / d,patients in the control group were treated with clopidogrel 75 mg / d. Thirty days later,two groups were given 75 mg / d as maintenance therapy. Plasma hs-CRP and Lp-PLA2 were detected and compared before PCI and 30 d after PCI. The adverse cardiovascular events and occurrence of bleeding were observed with 1-year follow-up. Results The two groups in death,myocardial infarction,target lesion revascularization aspect alone was no significant difference( P 0. 05). Adverse cardiovascular events in the observation group was 3. 7% and 9. 9% in the control group,and the two groups were significantly different( P 0. 05). Two groups of patients didn't have intracranial hemorrhage and gastrointestinal bleeding. The incidence of total bleeding events was 9. 9% in the observation group and 7. 4% in the control group,and with no significant difference( P 0. 05). The plasma hs-CRP and Lp-PLA2 of two groups in postpeative 30 d were significantly reduced( all P 0. 05 or 0. 01),and the observation group decreased more significantly than the control group after treatment( all P 0. 05). Conclusion Double-dose clopidogrel after PCI can significantly reduce the inflammation in patients with ACS and there is no severe adverse reaction.